OTCMKTS:NEVPF Abliva AB (publ) (NEVPF) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free NEVPF Stock Alerts $0.01 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.01▼$0.0150-Day Range$0.01▼$0.0252-Week Range$0.01▼$0.02VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartShort InterestStock AnalysisChartShort Interest Get Abliva AB (publ) alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Abliva AB (publ) Stock (OTCMKTS:NEVPF)Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.Read More NEVPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NEVPF Stock News HeadlinesMarch 20, 2024 | barrons.comProbi ABJanuary 10, 2024 | seekingalpha.comIVSXF Investor AB (publ)April 23, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.October 3, 2023 | investing.comInterfox Resources publ AB (IFOX)October 14, 2022 | investing.comCell Impact publ AB (CELLI)January 20, 2022 | nasdaq.comAbliva AB (publ) (NEVPF)See More Headlines Receive NEVPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abliva AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:NEVPF CUSIPN/A CIKN/A Webwww.neurovive.com Phone(646) 275-6220Fax46-4-688-883-48Employees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,450,000.00 Net MarginsN/A Pretax Margin-6,314,897.50% Return on Equity-63.75% Return on Assets-57.93% Debt Debt-to-Equity RatioN/A Current Ratio6.60 Quick Ratio6.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book0.25Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Ellen K. Donnelly Ph.D. (Age 50)Chief Executive Officer Comp: $4.97MMs. Catharina Jz Johansson (Age 57)Deputy CEO, CFO & VP of Investor Relations Dr. Eskil Elmér M.D. (Age 54)Ph.D., Chief Scientific Officer & VP of Discovery Comp: $247kDaniel SchaleDirector of CommunicationsDr. Magnus Hansson (Age 48)Chief Medical Officer and VP of Preclinical & Clinical Development Mr. Dag NesseVice President of Clinical OperationsDr. Lars VedinConsultantMore ExecutivesKey CompetitorsAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYAlseres PharmaceuticalsOTCMKTS:ALSEView All Competitors NEVPF Stock Analysis - Frequently Asked Questions How have NEVPF shares performed in 2024? Abliva AB (publ)'s stock was trading at $0.01 at the beginning of the year. Since then, NEVPF shares have increased by 0.0% and is now trading at $0.01. View the best growth stocks for 2024 here. How do I buy shares of Abliva AB (publ)? Shares of NEVPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NEVPF) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersPentagon contract could send this $2 AI stock soaringBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abliva AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
